Novo Nordisk | NVO - Ebit


Novo Nordisk reported DKK5.25B in EBIT for its fiscal quarter ending in June of 2026.





Ebit Change Date
ANI Pharmaceuticals USD 51.84M 12M Sep/2026
Aurora Cannabis CAD -3.17M 10.29M Jun/2026
Bausch Health Companies USD 993M 217M Sep/2026
Bristol-Myers Squibb USD 255M 44M Sep/2026
Canopy Growth CAD -2.03M 143.62M Jun/2026
Corcept Therapeutics USD 114.72M 73.42M Sep/2026
Drreddys Laboratories INR 13.52B 10.47B Sep/2026
Eli Lilly USD 13.09B 635M Sep/2026
GlaxoSmithKline GBP 2.86B 251M Sep/2026
Merck USD 7.33B 6.49B Sep/2026
Nektar Therapeutics USD -38.26M 19.17M Mar/2026
Novartis USD 5.14B 411M Sep/2026
Novo Nordisk DKK 33.76B 25.86B Jun/2026
Novo Nordisk DKK 5.25B 60.42B Jun/2026
Pacira USD 2.57B 2.56B Sep/2026
Perrigo USD 27.2M 116.6M Sep/2026
Phibro Animal Health USD 54.99M 2.36M Dec/2025
Prestige Brands USD 52.52M 22.97M Jun/2026
Sanofi EUR 4.72B 3.6B Sep/2026
Supernus Pharmaceuticals USD -21.04M 14.21M Jun/2026
Zoetis USD 1.03B 88M Sep/2026